Cargando…

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report

Detalles Bibliográficos
Autores principales:	Zirwas, Matthew J., Wulff, Katie, Beckman, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280680/ https://www.ncbi.nlm.nih.gov/pubmed/30555883 http://dx.doi.org/10.1016/j.jdcr.2018.10.016

Ejemplares similares

Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
por: Chung, Jou-Ku, et al.
Publicado: (2018)

Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management
por: Jay, Ryan, et al.
Publicado: (2022)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD),()()
por: Raffi, Jodie, et al.
Publicado: (2019)

Dupilumab-associated cicatrizing ocular disease
por: Reddy, Amit K., et al.
Publicado: (2022)

Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
por: Park, Sunny, et al.
Publicado: (2021)

Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
por: Popiela, Magdalena Z., et al.
Publicado: (2021)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols, Kelly K, et al.
Publicado: (2018)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)(,,)()
por: Raffi, Jodie, et al.
Publicado: (2019)

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022)

Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting
por: Foley, Peter, et al.
Publicado: (2022)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series
por: Hébert, Mélanie, et al.
Publicado: (2022)

Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study
por: Barbieri, John S., et al.
Publicado: (2021)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
por: Du, Guoxin, et al.
Publicado: (2022)

Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report
por: Adachi, Rumi, et al.
Publicado: (2022)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients
por: Tauqeer, Zujaja, et al.
Publicado: (2022)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab–Associated Conjunctivitis in Patients with Atopic Dermatitis
por: Patra, VijayKumar, et al.
Publicado: (2023)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

Practical Synthesis of 5,7-Dichlorotetrahydroisoquinoline-6-carboxylic Acid—Key Intermediate of Lifitegrast (Xiidra)
por: Liu, Xu, et al.
Publicado: (2023)

Dupilumab-Induced Pancreatitis
por: Jasti, Vivek V., et al.
Publicado: (2023)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah, Richard Teofilo, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Dupilumab-induced erythema nodosum
por: Mustin, Danielle E., et al.
Publicado: (2021)

Dupilumab-induced pityriasis rosea
por: Zabel, Morgan, et al.
Publicado: (2023)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
por: Park, Jonathan J., et al.
Publicado: (2023)

Dupilumab for the treatment of pembrolizumab‐induced bullous pemphigoid: A case report
por: Pop, Samantha R., et al.
Publicado: (2022)

Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis
por: Jia, Qian-Nan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jf5vb3h78c232s96kaburj8i61